Sheila M Keating1,2, Richard Brad Jones3, Christina M Lalama4, Ronald J Bosch4, Deborah McMahon5, Dylan Hampton1, Joshua Cyktor5, Joseph J Eron6, John W Mellors5, Michael P Busch1,2, Rajesh T Gandhi7. 1. Blood Systems Research Institute, San Francisco, CA. 2. Department of Laboratory Medicine, University of California, San Francisco, CA. 3. Division of Infectious Diseases, Weill Cornell Medicine, New York. 4. Harvard T.H. Chan School of PH, Boston, MA. 5. Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA. 6. Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC. 7. Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA.
Abstract
BACKGROUND: In people with HIV on antiretroviral therapy (ART), the relationship between HIV-specific immune responses and measures of HIV persistence is uncertain. METHODS: We evaluated 101 individuals on suppressive ART in the AIDS Clinical Trials Group A5321 cohort. Cell-associated (CA) HIV DNA and RNA levels and HIV antibody concentrations and avidity to Env/p24 were measured longitudinally at years 1, 4, and 6-15 after ART initiation. Plasma HIV RNA by single copy assay and T-cell responses (IFN-γ ELISPOT) against multiple HIV antigens were measured at the last time point. RESULTS: HIV antibody levels declined significantly with increasing time on ART (19%/year between year 1 and 4). HIV antibody levels correlated with T-cell responses to HIV Pol (r = 0.28, P = 0.014) and to Nef/Tat/Rev (r = 0.34; P = 0.002). HIV antibody and T-cell responses were positively associated with HIV DNA levels; for example, at the last time point (median 7 years on ART), r = 0.35 for antibody levels and HIV DNA (P < 0.001); r = 0.23 for Nef/Tat/Rev-specific T-cell responses and HIV DNA (P = 0.03). Neither antibody nor T-cell responses correlated with cell-associated HIV RNA or plasma RNA by single copy assay. CONCLUSIONS: In individuals on long-term ART, HIV-specific antibody and T-cell responses correlate with each other and with HIV DNA levels. The positive correlation between HIV immune responses and HIV DNA implies that the immune system is sensing, but not clearing, infected cells, perhaps because of immune dysfunction. Measuring immune responses to HIV antigens may provide insight into the impact of reservoir-reducing strategies.
BACKGROUND: In people with HIV on antiretroviral therapy (ART), the relationship between HIV-specific immune responses and measures of HIV persistence is uncertain. METHODS: We evaluated 101 individuals on suppressive ART in the AIDS Clinical Trials Group A5321 cohort. Cell-associated (CA) HIV DNA and RNA levels and HIV antibody concentrations and avidity to Env/p24 were measured longitudinally at years 1, 4, and 6-15 after ART initiation. Plasma HIV RNA by single copy assay and T-cell responses (IFN-γ ELISPOT) against multiple HIV antigens were measured at the last time point. RESULTS:HIV antibody levels declined significantly with increasing time on ART (19%/year between year 1 and 4). HIV antibody levels correlated with T-cell responses to HIV Pol (r = 0.28, P = 0.014) and to Nef/Tat/Rev (r = 0.34; P = 0.002). HIV antibody and T-cell responses were positively associated with HIV DNA levels; for example, at the last time point (median 7 years on ART), r = 0.35 for antibody levels and HIV DNA (P < 0.001); r = 0.23 for Nef/Tat/Rev-specific T-cell responses and HIV DNA (P = 0.03). Neither antibody nor T-cell responses correlated with cell-associated HIV RNA or plasma RNA by single copy assay. CONCLUSIONS: In individuals on long-term ART, HIV-specific antibody and T-cell responses correlate with each other and with HIV DNA levels. The positive correlation between HIV immune responses and HIV DNA implies that the immune system is sensing, but not clearing, infected cells, perhaps because of immune dysfunction. Measuring immune responses to HIV antigens may provide insight into the impact of reservoir-reducing strategies.
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: Feiyu Hong; Evgenia Aga; Anthony R Cillo; Aarika L Yates; Guillaume Besson; Elizabeth Fyne; Dianna L Koontz; Cheryl Jennings; Lu Zheng; John W Mellors Journal: J Clin Microbiol Date: 2016-01-13 Impact factor: 5.948
Authors: Anthony R Cillo; David Vagratian; Margaret A Bedison; Elizabeth M Anderson; Mary F Kearney; Elizabeth Fyne; Dianna Koontz; John M Coffin; Michael Piatak; John W Mellors Journal: J Clin Microbiol Date: 2014-09-03 Impact factor: 5.948
Authors: Yen T Duong; Maofeng Qiu; Anindya K De; Keisha Jackson; Trudy Dobbs; Andrea A Kim; John N Nkengasong; Bharat S Parekh Journal: PLoS One Date: 2012-03-27 Impact factor: 3.240
Authors: Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors Journal: PLoS Pathog Date: 2007-04 Impact factor: 6.823
Authors: Adam R Ward; Allison S Thomas; Eva M Stevenson; Szu-Han Huang; Sheila M Keating; Rajesh T Gandhi; Deborah K McMahon; Ronald J Bosch; Bernard J Macatangay; Joshua C Cyktor; Joseph J Eron; John W Mellors; R Brad Jones Journal: AIDS Date: 2022-06-22 Impact factor: 4.632
Authors: Szu-Han Huang; Chase D McCann; Talia M Mota; Chao Wang; Steven M Lipkin; R Brad Jones Journal: Front Immunol Date: 2019-08-06 Impact factor: 7.561
Authors: Geoffrey T Ivison; Elena Vendrame; Giovanny J Martínez-Colón; Thanmayi Ranganath; Rosemary Vergara; Nancy Q Zhao; Maureen P Martin; Sean C Bendall; Mary Carrington; Joshua C Cyktor; Deborah K McMahon; Joseph Eron; R Brad Jones; John W Mellors; Ronald J Bosch; Rajesh T Gandhi; Susan Holmes; Catherine A Blish Journal: Front Cell Infect Microbiol Date: 2022-02-10 Impact factor: 6.073
Authors: Ashley N Nelson; Maria Dennis; Jesse F Mangold; Katherine Li; Pooja T Saha; Kenneth Cronin; Kaitlyn A Cross; Amit Kumar; Riley J Mangan; George M Shaw; Katharine J Bar; Barton Haynes; Anthony M Moody; S Munir Alam; Justin Pollara; Michael G Hudgens; Koen K A Van Rompay; Kristina De Paris; Sallie R Permar Journal: NPJ Vaccines Date: 2022-07-30 Impact factor: 9.399
Authors: Marta Calvet-Mirabent; Ildefonso Sánchez-Cerrillo; Noa Martín-Cófreces; Pedro Martínez-Fleta; Hortensia de la Fuente; Ilya Tsukalov; Cristina Delgado-Arévalo; María José Calzada; Ignacio de Los Santos; Jesús Sanz; Lucio García-Fraile; Francisco Sánchez-Madrid; Arantzazu Alfranca; María Ángeles Muñoz-Fernández; Maria J Buzón; Enrique Martín-Gayo Journal: EBioMedicine Date: 2022-06-02 Impact factor: 11.205